Comparative Pharmacology
Head-to-head clinical analysis: BREXAFEMME versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREXAFEMME versus DIETHYLSTILBESTROL.
BREXAFEMME vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREXAFEMME (ibrexafungerp) inhibits glucan synthase, an enzyme involved in fungal cell wall synthesis, disrupting cell wall integrity and causing fungal cell death.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
200 mg orally once daily.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
The terminal elimination half-life of ibrexafungerp is approximately 20-30 hours in healthy subjects, supporting once-daily oral dosing without need for a loading dose.
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Ibrexafungerp is primarily eliminated via the biliary/fecal route. In clinical studies, approximately 51% of the dose was recovered in feces (as unchanged drug and metabolites) and ~1% in urine. Renal excretion is negligible.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."